S&P 500   4,292.77 (+0.29%)
DOW   33,909.70 (+0.44%)
QQQ   332.36 (+0.60%)
AAPL   173.06 (+0.56%)
MSFT   293.09 (+0.40%)
META   180.79 (+0.16%)
GOOGL   122.06 (+0.31%)
AMZN   142.86 (-0.48%)
TSLA   933.14 (+3.67%)
NVDA   188.55 (+0.78%)
NIO   21.30 (+0.90%)
BABA   94.10 (-0.71%)
AMD   100.52 (-0.31%)
MU   64.49 (-0.85%)
T   18.44 (+0.93%)
CGC   3.86 (+16.97%)
GE   79.73 (-0.25%)
F   16.34 (+0.99%)
DIS   124.50 (+2.41%)
AMC   23.96 (-1.96%)
PYPL   101.42 (+0.32%)
PFE   49.57 (-1.08%)
NFLX   248.76 (-0.22%)
S&P 500   4,292.77 (+0.29%)
DOW   33,909.70 (+0.44%)
QQQ   332.36 (+0.60%)
AAPL   173.06 (+0.56%)
MSFT   293.09 (+0.40%)
META   180.79 (+0.16%)
GOOGL   122.06 (+0.31%)
AMZN   142.86 (-0.48%)
TSLA   933.14 (+3.67%)
NVDA   188.55 (+0.78%)
NIO   21.30 (+0.90%)
BABA   94.10 (-0.71%)
AMD   100.52 (-0.31%)
MU   64.49 (-0.85%)
T   18.44 (+0.93%)
CGC   3.86 (+16.97%)
GE   79.73 (-0.25%)
F   16.34 (+0.99%)
DIS   124.50 (+2.41%)
AMC   23.96 (-1.96%)
PYPL   101.42 (+0.32%)
PFE   49.57 (-1.08%)
NFLX   248.76 (-0.22%)
S&P 500   4,292.77 (+0.29%)
DOW   33,909.70 (+0.44%)
QQQ   332.36 (+0.60%)
AAPL   173.06 (+0.56%)
MSFT   293.09 (+0.40%)
META   180.79 (+0.16%)
GOOGL   122.06 (+0.31%)
AMZN   142.86 (-0.48%)
TSLA   933.14 (+3.67%)
NVDA   188.55 (+0.78%)
NIO   21.30 (+0.90%)
BABA   94.10 (-0.71%)
AMD   100.52 (-0.31%)
MU   64.49 (-0.85%)
T   18.44 (+0.93%)
CGC   3.86 (+16.97%)
GE   79.73 (-0.25%)
F   16.34 (+0.99%)
DIS   124.50 (+2.41%)
AMC   23.96 (-1.96%)
PYPL   101.42 (+0.32%)
PFE   49.57 (-1.08%)
NFLX   248.76 (-0.22%)
S&P 500   4,292.77 (+0.29%)
DOW   33,909.70 (+0.44%)
QQQ   332.36 (+0.60%)
AAPL   173.06 (+0.56%)
MSFT   293.09 (+0.40%)
META   180.79 (+0.16%)
GOOGL   122.06 (+0.31%)
AMZN   142.86 (-0.48%)
TSLA   933.14 (+3.67%)
NVDA   188.55 (+0.78%)
NIO   21.30 (+0.90%)
BABA   94.10 (-0.71%)
AMD   100.52 (-0.31%)
MU   64.49 (-0.85%)
T   18.44 (+0.93%)
CGC   3.86 (+16.97%)
GE   79.73 (-0.25%)
F   16.34 (+0.99%)
DIS   124.50 (+2.41%)
AMC   23.96 (-1.96%)
PYPL   101.42 (+0.32%)
PFE   49.57 (-1.08%)
NFLX   248.76 (-0.22%)
NASDAQ:EYEN

Eyenovia - EYEN Stock Forecast, Price & News

$1.69
-0.02 (-1.17%)
(As of 08/15/2022 01:45 PM ET)
Add
Compare
Today's Range
$1.64
$1.72
50-Day Range
$1.63
$2.20
52-Week Range
$1.59
$6.63
Volume
6,936 shs
Average Volume
122,107 shs
Market Capitalization
$56.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Eyenovia MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
429.4% Upside
$9.00 Price Target
Short Interest
Healthy
0.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of Eyenovia in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$179,210 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.81) to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

278th out of 1,128 stocks

Pharmaceutical Preparations Industry

132nd out of 554 stocks

EYEN stock logo

About Eyenovia (NASDAQ:EYEN) Stock

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

Eyenovia Trading Down 0.6 %

Shares of NASDAQ:EYEN traded down $0.01 during mid-day trading on Monday, reaching $1.70. 6,435 shares of the company's stock were exchanged, compared to its average volume of 122,107. The firm has a market capitalization of $57.07 million, a price-to-earnings ratio of -3.00 and a beta of 1.89. The business has a fifty day simple moving average of $1.80 and a 200 day simple moving average of $2.38. Eyenovia has a twelve month low of $1.59 and a twelve month high of $6.63.

Eyenovia (NASDAQ:EYEN - Get Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.24) EPS for the quarter. Equities research analysts predict that Eyenovia will post -0.81 earnings per share for the current fiscal year.

Insider Transactions at Eyenovia

In other Eyenovia news, major shareholder Stuart M. Grant purchased 100,000 shares of the company's stock in a transaction dated Tuesday, June 21st. The shares were bought at an average price of $1.65 per share, with a total value of $165,000.00. Following the completion of the transaction, the insider now directly owns 5,084,998 shares in the company, valued at approximately $8,390,246.70. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.00% of the stock is currently owned by insiders.

Receive EYEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter.

EYEN Stock News Headlines

Elon Musk is Worried about China
China controls 80% of the lithium market and Tesla needs a lot of lithium for its cars. But a junior miner just discovered a once-in-a-lifetime deposit of this "white gold."
Eyenovia Reports Second Quarter 2022 Financial Results
Elon Musk is Worried about China
China controls 80% of the lithium market and Tesla needs a lot of lithium for its cars. But a junior miner just discovered a once-in-a-lifetime deposit of this "white gold."
See More Headlines
Receive EYEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter.

EYEN Company Calendar

Last Earnings
11/10/2021
Today
8/15/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYEN
Fax
N/A
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+432.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-12,780,000.00
Pretax Margin
-171.64%

Debt

Sales & Book Value

Annual Sales
$14 million
Book Value
$0.72 per share

Miscellaneous

Free Float
27,370,000
Market Cap
$56.73 million
Optionable
Not Optionable
Beta
1.89














EYEN Stock - Frequently Asked Questions

Should I buy or sell Eyenovia stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYEN shares.
View EYEN analyst ratings
or view top-rated stocks.

What is Eyenovia's stock price forecast for 2022?

1 brokerages have issued 1 year target prices for Eyenovia's shares. Their EYEN share price forecasts range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 426.3% from the stock's current price.
View analysts price targets for EYEN
or view top-rated stocks among Wall Street analysts.

How have EYEN shares performed in 2022?

Eyenovia's stock was trading at $4.00 at the start of the year. Since then, EYEN shares have decreased by 57.3% and is now trading at $1.71.
View the best growth stocks for 2022 here
.

When is Eyenovia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our EYEN earnings forecast
.

How were Eyenovia's earnings last quarter?

Eyenovia, Inc. (NASDAQ:EYEN) announced its earnings results on Wednesday, November, 10th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. During the same period in the previous year, the firm earned ($0.23) earnings per share.

What other stocks do shareholders of Eyenovia own?

When did Eyenovia IPO?

(EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ acted as the underwriters for the IPO.

What is Eyenovia's stock symbol?

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

Who are Eyenovia's major shareholders?

Eyenovia's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.46%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Charles E Iv Mather, John P Gandolfo, Kenneth B Lee Jr, Michael M Rowe, Michael M Rowe, Stuart M Grant, Stuart M Grant and Tsontcho Ianchulev.
View institutional ownership trends
.

How do I buy shares of Eyenovia?

Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eyenovia's stock price today?

One share of EYEN stock can currently be purchased for approximately $1.71.

How much money does Eyenovia make?

Eyenovia (NASDAQ:EYEN) has a market capitalization of $57.40 million and generates $14 million in revenue each year. The company earns $-12,780,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How can I contact Eyenovia?

Eyenovia's mailing address is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. The official website for the company is www.eyenoviabio.com. The company can be reached via phone at (917) 289-1117 or via email at tbui@theruthgroup.com.

This page (NASDAQ:EYEN) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.